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Abstract Most lipid emulsions for parenteral feeding of
premature infants are based on long-chain triacylglycerols
(LCTs), but inclusion of medium-chain triacylglycerols
(MCTs) might provide a more readily oxidizable energy
source. The influence of these emulsions on fatty acid com-
position and metabolism was studied in 12 premature neo-
nates, who were randomly assigned to an LCT emulsion
(control) or an emulsion with a mixture of MCT and LCT
(1:1). On study day 7, all infants received [13C]linoleic (LA)
and [13C]A-linolenic acid (ALA) tracers orally. Plasma phos-
pholipid (PL) and triacylglycerol (TG) fatty acid composi-
tion and13C enrichments of plasma PL fatty acids were
determined on day 8. After 8 days of lipid infusion, plasma
TGs in the MCT/LCT group had higher contents of C8:0
(0.50 6 0.60% vs. 0.10 6 0.12%; means 6 SD) and C10:0
(0.66 6 0.51% vs. 0.15 6 0.17%) than controls. LA content
of plasma PLs was slightly lower in the MCT/LCT group
(16.47 6 1.16% vs. 18.57 6 2.09%), whereas long-chain
polyunsaturated derivatives (LC-PUFAs) of LA and ALA
tended to be higher. The tracer distributions between pre-
cursors and products (LC-PUFAs) were not significantly
different between groups. Both lipid emulsions achieve
similar plasma essential fatty acid (EFA) contents and similar
proportional conversion of EFAs to LC-PUFAs. The MCT/
LCT emulsion seems to protect EFAs and LC-PUFAs from
b-oxidation.—Lehner, F., H. Demmelmair, W. Röschinger,
T. Decsi, M. Szász, K. Adamovich, R. Arnecke, and B.
Koletzko. Metabolic effects of intravenous LCT or MCT/
LCT lipid emulsions in preterm infants. J. Lipid Res. 2006.
47: 404–411.
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For many pediatric patients, parenteral nutrition is an
essential and often lifesaving therapy (1). Parenteral nu-
trition of infants and children depends on the use of lipid
emulsions that provide a high energy density in an isotonic
solution and supply essential fatty acids (EFAs) and fat-
soluble vitamins. In premature infants, EFA body stores
are very low, whereas their metabolic requirements are
high; therefore, EFA supply is of critical importance (2).
Conventional fat emulsions for premature neonates are
prepared from long-chain triacylglycerols (LCTs), mostly
soybean oil. An emulsion based on physical mixtures of
LCT and medium-chain triacylglycerols (MCTs) is widely
used for the parenteral nutrition of adult patients and
provides an energy source that is rapidly oxidized (3). The
MCT/LCT emulsion provides less PUFA than an LCT
emulsion and thus has been associated with a lower risk of
lipid peroxidation and fewer alterations of membrane
structures (4). High amounts of linoleic acid (LA; C18:2n-
6) and a-linolenic acid (ALA; C18:3n-3) were reported to
inhibit D6 desaturation, the initial step in the formation
of long-chain polyunsaturated fatty acids (LC-PUFAs) (5).
Thus, we hypothesized that a reduced supply of LA and
ALA with the MCT/LCT emulsion might enhance LC-
PUFA formation.
Because of the fast growth of brain and retina during
the perinatal period, an inadequate supply of LC-PUFAs,
mainly arachidonic acid (AA; C20:4n-6) and docosahexa-
enoic acid (DHA; C22:6n-3), may have profound effects
on the development of brain and visual function in pre-
term infants (6, 7). Although infants are able to synthesize
LC-PUFAs from LA (C18:2n-6) and ALA (C18:3n-3) by
desaturation and elongation from the first postnatal week
onward, the rate of synthesis is rather low relative to the
requirements for tissue incorporation (8, 9).
In human adults, infused MCTs are oxidized faster and
to a greater extent than LCTs (10), but data on their me-
tabolism in infants are scarce (1, 11). We hypothesized
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that in preterm infants the supply of a MCT/LCT emul-
sion would result in predominant oxidation of MCT,
rather than LCT, as a major energy source; thus, via
decreased LCT oxidation, the lower LCT intake might be
partly compensated for by a higher availability of LCT for
structural functions and for conversion into LC-PUFAs.
In this randomized study in preterm infants who re-
ceived total parenteral nutrition for 8 days, we compared
the effects of a MCT/LCT-based emulsion and of a LCT
emulsion on the fatty acid composition of plasma phos-
pholipids (PLs) and triacylglycerols (TGs). For a more
detailed description of the metabolism of EFAs and their
LC-PUFA derivatives, we applied 13C-labeled fatty acid
tracers, which allow for the comparison of endogenous
LC-PUFA synthesis under different conditions (12, 13).
SUBJECTS AND METHODS
Premature neonates were recruited in the Division of Neona-
tology at the University of Pécs. Inclusion criteria for the study
were as follows: gestational age between 25 and 37 weeks; birth
weight , 3,000 g; the indication for total parenteral feeding (ex-
pected enteral feeding , 20% of daily energy intake) for at least
8 days; and the intention to supply a lipid emulsion within 48 h
after birth. Infants with known metabolic diseases were excluded.
In this randomized, double-blind trial, premature infants were
assigned either to the control group, receiving a conventional
20% LCT fat emulsion (soybean oil; Lipofundin N 20%T), or to
the MCT/LCT group, which received a 20% MCT/LCT emulsion
[a physical mixture (1:1 by weight) of soybean oil and coconut
oil; Lipofundin MCT 20%] (Table 1). The parenteral nutrition
also provided 10% glucose, amino acids, electrolytes (sodium
chloride, potassium chloride, calcium gluconate), trace elements
(Ped-elT; Pharmacia, Budapest, Hungary), and water-soluble
vitamins (SoluvitT; Baxter, Deerfield, IL).
On day 7 of the study, 10 mg/kg body weight of uniformly 13C-
labeled (98%) LA and 2 mg/kg body weight of uniformly 13C-
labeled (98%) ALA (Martek Bioscience Corp., Columbia, MD)
were given orally to the infants, dissolved in a small volume of
human milk. Blood samples were obtained on day 1 (before in-
troducing the study emulsions), on day 7 (before tracer appli-
cation), and on day 8. Biochemical safety parameters were
measured on each day of the study (data not shown). The study
protocol was approved by the ethical committee of the University
of Pécs, and written informed consent was obtained from the
parents of each infant before study entry.
Blood samples
Blood samples were obtained by venipuncture and collected in
EDTA tubes. Plasma and red blood cells were separated by cen-
trifugation at 1,500 g for 5 min. An aliquot was used to measure
plasma lipids (cholesterol, total TG, total PL, and total nonester-
ified fatty acids) and 3-hydroxybutyrate. The enzymatic analyses
were performed in Pécs with standard clinical chemistry methods
(Lipid-Kits from Boehringer Mannheim, Mannheim, Germany).
Plasma free carnitine and acylcarnitines were determined by
electrospray tandem mass spectrometry (14, 15), and a- and g-
tocopherol were determined by high-performance liquid chro-
matography from 100 Al of plasma (16).
For the analysis of plasma fatty acids, an internal standard was
added to the samples (trinonanoin for the quantification of C8:0,
C10:0, and C12:0 in TG, dipentadecanoylphosphatidylcholine
and tripentadecanoin for the quantification of fatty acids with 14
or more carbon atoms; Sigma, St. Louis, MO). Samples were
extracted with hexane-isopropanol, as described previously (17).
Plasma PLs and TGs were isolated by thin-layer chromatography
(18). For transesterification, TGs were dissolved in a methanolic
HCl/hexane mixture, whereas for the transesterification of PL,
pure methanolic HCl was used. After cooling of the mixture,
water was added to TG samples to achieve phase separation and
an aliquot of the organic phase was used for gas chromatography
analysis. Evaporation steps were omitted in the preparation of FA
methylesters from TG, to avoid losses of volatile medium-chain
fatty acids. After cooling of the PL samples, the reactant mixture
was neutralized with a dry carbonate buffer. Methylesters were
extracted twice into hexane, dried under nitrogen, and taken up
in hexane containing 2,6-di-tert-butyl-4-kresol for gas chromato-
graphic analysis (19).
Gas-liquid chromatography and mass spectrometry
An HP 5890 II gas chromatograph (Hewlett-Packard, Wald-
bronn, Germany), equipped with a split/splitless injector, a
flame ionization detector, and a BPX70 column (length, 60 m;
inner diameter, 0.32 mm; SGE, Weiterstadt, Germany), was used
for quantitative analyses. The temperature program started at
130jC and increased at 3 K per minute up to 210jC. Fatty acid
methylesters were identified by comparison of the retention
times with those of authentic standard compounds.
13C contents in plasma PL fatty acid methylesters were de-
termined by gas chromatography-combustion-isotope ratio mass
spectrometry using an HP 5890 II gas chromatograph and a
Finnigan MAT delta S isotope ratio mass spectrometer (Thermo
Finnigan, Bremen, Germany) (9). Samples were analyzed in
duplicate, and further calculations were performed with the
means of the y13C values (%) obtained.
Calculations
The y13C (%) value is the deviation of the 13C/12C ratio (RFA)
of a sample from the 13C/12C ratio (RPDB) of the PDB (Pee Dee
Belmnite) standard in relation to the ratio of the international
PDB standard (20):
d13CFA[%] 5 [(RFA  RPDB)/RPDB] 1,000
TABLE 1. Composition of the two fat emulsions used (data as













Monounsaturated fatty acids (%, w/w)
C18:1n-9 24 12
Polyunsaturated fatty acids (%, w/w)
C18:2n-6 50 27
C18:3n-3 7 4
Other fatty acids (%, w/w) 2.5 –
Emulsifier (g/l) 12 12
Glycerin (g/l) 25 25
Phosphate (mmol/l) 13 13
a-Tocopherol (mg/l) 227 208
LCT, long-chain triacylglycerol; MCT, medium-chain triacylglycerol.
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The atom percent 13C (APFA; %) of the fatty acid methylester
was calculated as the percentage content of 13C relative to total C:
APFA 5 RFA/(1 þ RFA) 100
13C contents on day 7 were used as baseline values and sub-
tracted from the values on day 8 to obtain tracer-induced atom
percent excess (APEFA):
APEFA 5 APFA day 8  APFA day 7
Absolute tracer concentrations in plasma PL fatty acids were
calculated as Amol of 13C derived from the tracer in each fatty
acid per liter of plasma:
tracer 13CFA½mmol/l 5 mMolFA
 (number of carbon atoms of FA þ 1) APEFA/100
Statistical analyses
Statistical analyses were performed using SAS (SAS System for
Windows, release 6.12; SAS Institute, Inc., Cary, NC). Results are
given as means 6 SD. Differences between the two feeding
groups were examined by the U-Mann-Whitney-Wilcoxon test.
Significant differences over time within one feeding group were
examined by paired t-tests. Statistical significance was assumed at
P , 0.05.
RESULTS
Fifteen infants were enrolled and randomized, and 12 (6
per group) completed the study according to the protocol
(Table 2). Three infants, all assigned to the MCT/LCT
group, were excluded because of wrong randomization,
breaching of the study conditions, and contraindication
against the feeding protocol (one infant each). No dropout
was related to any adverse effects of the study medication.
In the control group, birth weights were appropriate for
gestational age in five infants and small for gestational age
in one, whereas all infants in the MCT/LCT group had
birth weights appropriate for gestational age. At baseline,
the MCT/LCT group tended to have a lower body weight
than the control group, which was preserved until day 8
(Table 2) and day 10 (1,545 6 140 g vs. 1,802 6 282 g).
Z-scores for body weight were calculated based on data
from the longitudinal study of Kramer et al. (21) and
showed no group differences (Table 2). Average daily
nutrient intakes for days 1–9 are shown in Table 3.
TG levels of the two groups were similar (Table 4) and
within the range of reference values (22), and no hyper-
triacylglycerolemia was observed. Plasma cholesterol con-
centrations were within the reference range (22). During
the study period, cholesterol levels increased significantly
to 3.23 6 0.83 mmol/l in the MCT/LCT group and to
3.37 6 0.64 mmol/l in the control group. Nonesterified
fatty acid levels were not different between the two groups
or between study time points. 3-Hydroxybutyrate con-
centrations decreased during the study period in the con-
trol group. Free carnitine and acylcarnitine concentrations
were similar in the two groups. Neither free carnitine nor
total carnitine or individual acylcarnitines decreased sig-
nificantly from day 1 to day 8 in either group.
At study start, the control group had significantly lower
levels of g-tocopherol (0.57 Amol/l vs. not detectable,
control vs. MCT/LCT group, respectively), whereas there
were no differences ina-tocopherol (10.94 vs. 8.65Amol/l).
In both groups a- and g-tocopherol levels increased sig-
nificantly during the study period (at day 8, 54.16 Amol/l
a-tocopherol and 17.13 Amol/l g-tocopherol in controls,
49.48 Amol/l a-tocopherol and 9.55 Amol/l g-tocopherol
in the MCT/LCT group), with no significant group dif-
ferences on day 8.
There were no significant differences between groups in
percentage values of PL fatty acids at baseline, but LA and
g-linolenic acid values on day 8 were significantly higher
in the LCT group (Table 5). Despite a 50% lower LA
(C18:2n-6) and ALA (C18:3n-3) supply with the MCT/
LCT emulsion, LA (C18:2n-6) levels increased to a similar
3-fold extent in both groups from day 1 to day 8. ALA
(C18:3n-3) levels showed a marked, 13-fold increase in the
MCT/LCT group and an 8-fold increase in the LCT group.
On day 8, the MCT/LCT group showed significantly
higher levels of medium-chain fatty acids (C8:0 and C10:0).
MUFAs and PUFAs in plasma TG were not different on day 1,
with the exception of eicosanoic acid (C20:0) (Table 6). In
both groups, LA (C18:2n-6) and ALA (C18:3n-3) in PL and
TG increased significantly from baseline to day 8, whereas
AA (C20:4n-6) and DHA (C22:6n-3) decreased. In the MCT/
TABLE 3. Mean daily energy and nutrient intake [mean (SD)] of the








Energy (kJ/day) 454.0 (164.8) 378.9 (137.1)
Amino acids (g/kg/day) 1.6 (0.7) 1.6 (0,8)
Fat (g/kg/day) 2.3 (1.3) 2.3 (1.2)
Glucose (g/kg/day) 9.1 (1.6) 9.1 (1.7)
Enteral intake
Energy (kJ/day) 69.9 (30.4) 62.0 (29.7)
Human milk (ml/day) 20.9 (9.0) 20.9 (6.3)
Intake of total liquid (ml/kg/day) 134.4 (43.2) 134.8 (45.2)
Proportion of enteral energy of total
energy (%)
13.7 (3.5) 14.4 (5.0)
Total energy intake (kJ/kg/day) 289.6 (115.2) 289.6 (120.4)
TABLE 2. Clinical characteristics and anthropometric data [mean
(SD)] of infants at birth and at study start, showing no significant
differences between groups
Characteristics LCT (n 5 6) MCT/LCT (n 5 6)
Male/female 3/3 6/–
Birth
Gestational age (weeks) 33.2 (1.0) 31.4 (1.6)a
Weight (g) 1,781.7 (290.3) 1,573.3 (169.8)
Z-score weight 0.33 (0.65) 0.81 (1.22)
Study start
Weight (g) 1780.0 (297.5)b 1575.0 (183.4)b
Z-score weight 1.16 (1.42)b 0.35 (0.91)b
Height (cm) 41.3 (2.9) 39.8 (1.0)
Day 8
Weight (g) 1791.7 (296.6) 1490.0 (145.1)
Z-score weight 0.79 (1.20) 0.78 (0.70)a
a n 5 5.
b n 5 3.
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LCT group, there was a trend toward higher LC-PUFA con-
tents in TG and PL, with significantly higher levels of C20:
2n-6 and DHA (C22:6n-3) in TG.
At 24 h after tracer administration, infants in the MCT/
LCT group had significantly higher 13C APE values and
13C tracer concentrations in plasma PL fatty acids than
infants receiving the LCT emulsion (Figs. 1, 2).
DISCUSSION
This study shows that infants receiving the MCT/LCT
lipid emulsion, with half the EFA supply than in the LCT
emulsion, have similar EFA contents in plasma PL and TG,
whereas LC-PUFA levels tend to be higher. Thus, MCTs
seem to enhance EFA and LC-PUFA incorporation into
circulating lipids.
Both lipid emulsions were well tolerated in the infants
that we followed, similar to observations made in previous
studies (23). Compared with the control group, the MCT/
LCT group tended toward a lower body weight at baseline
(NS), showed a greater weight loss, and regained birth
weight later, although the extent of parenteral nutrition
and caloric intake was comparable in the two groups.
Postnatal weight loss during the first days of life reflects
primarily the loss of relatively expanded fetal water com-
TABLE 5. Fatty acid composition of plasma PLs in preterm infants before (day 1) and after (day 8) LCT (control)
or MCT/LCT emulsion
Day 1 Day 8
Composition LCT (n 5 6) MCT/LCT (n 5 6) LCT (n 5 6) MCT/LCT (n 5 6)
Saturated fatty acids
A saturated fatty acids 49.82 (1.45) 48.60 (0.95) 47.56 (0.70) 46.64 (0.86)
Monounsaturated fatty acids
C18:1n-9 10.06 (1.90) 10.49 (2.27) 13.48 (1.46)a 14.32 (0.73)b
A MUFA 17.09 (2.62) 18.68 (2.66) 18.29 (0.93) 19.09 (0.88)
Polyunsaturated fatty acids
C20:3n-9 0.62 (0.31) 0.79 (0.46) 0.16 (0.10)b 0.19 (0.06)a
n-6 PUFAs
C18:2n-6 6.64 (0.86) 5.41 (1.24) 18.57 (2.09)b 16.47 (1.16)b,c
C18:3n-6 0.05 (0.04) 0.07 (0.03) 0.20 (0.04)b 0.13 (0.02)b,c
C20:2n-6 0.26 (0.05) 0.24 (0.05) 0.40 (0.04)b 0.41 (0.04)b
C20:3n-6 2.70 (0.56) 2.64 (0.44) 1.78 (0.56)b 1.88 (0.23)a
C20:4n-6 17.34 (1.72) 17.97 (2.89) 8.81 (2.10)b 9.99 (0.85)b
C22:2n-6 0.10 (0.09) 0.04 (0.01) 0.11 (0.02) 0.10 (0.02)b
C22:4n-6 0.56 (0.10) 0.62 (0.11) 0.40 (0.06)b 0.43 (0.02)a
C22:5n-6 0.71 (0.28) 0.79 (0.20) 0.59 (0.09) 0.65 (0.04)
n-3 PUFAs
C18:3n-3 0.02 (0.05) 0.00 (0.00) 0.15 (0.03)b 0.13 (0.05)b
C20:3n-3 0.11 (0.06) 0.15 (0.04) 0.07 (0.03)a 0.08 (0.02)b
C20:5n-3 0.10 (0.06) 0.12 (0.06) 0.20 (0.06)b 0.17 (0.02)
C22:5n-3 0.08 (0.03) 0.08 (0.04) 0.24 (0.04)b 0.25 (0.03)b
C22:6n-3 3.39 (0.50) 3.48 (0.86) 2.32 (0.36)b 2.61 (0.28)a
A PUFA 32.80 (1.99) 32.28 (3.38) 33.67 (1.33) 33.79 (0.94)
A PUFA 5 C18:2n-6 + C18:3n-6 + C20:2n-6 + C20:3n-6 + C20:4n-6 + C22:4n-6 + C22:5n-6 + C18:3n-3 +
C20:3n-3 + C20:5n-3 + C22:5n-3 + C22:6n-3. Values shown are means (SD) (%, w/w).
a P , 0.05 day 8 versus day 1 within one group.
b P , 0.01 day 8 versus day 1 within one group.
c P , 0.05 MCT versus control.
TABLE 4. Plasma concentrations [mean (SD)] of TGs, cholesterol, PLs, nonesterified fatty acids,
3-hydroxybutyrate, free carnitine, and acylcarnitines of the studied infants before lipid
infusion (day 1) and 24 h after the end of lipid infusion (day 8)
Day 1 Day 8
Variable LCT(n 5 6)
MCT/LCT
(n 5 6) LCT (n 5 6)
MCT/LCT
(n 5 6)
TGs (mmol/l) 0.68 (0.17) 0.72 (0.23) 1.18 (0.53) 0.67 (0.10)
PLs (mg/l) 1,950.7 (352.6) 2,084.7 (733.9) 2,212.5 (329.9) 2,240.8 (605.7)
Cholesterol (mmol/l) 2.12 (1.05) 2.30 (0.89) 3.37 (0.64)a 3.23 (0.83)b
Nonesterified fatty acids (Amol/l) 466.8 (118.5) 795.0 (446.6) 499.2 (145.2) 746.5 (337.5)
3-Hydroxybutyrate (mmol/l) 73.17 (14.16) 90.33 (63.46) 48.33 (8.24)a 53.00 (11.90)
Free carnitine (Amol/l) 18.90 (6.39) 14.62 (9.71) 9.94 (3.11) 10.63 (3.48)
A acylcarnitines (Amol/l) 12.79 (5.44) 11.95 (4.52) 9.60 (3.39) 8.45 (1.59)
A medium chain (Amol/l) 0.30 (0.20) 0.59 (0.46) 0.53 (0.25) 0.50 (0.14)
A long chain (Amol/l) 0.30 (0.20) 0.32 (0.21) 0.14 (0.04) 0.15 (0.02)
Ratio of A acylcarnitines to free carnitine 0.68 (0.12) 1.13 (1.02) 1.00 (0.34) 0.84 (0.24)
PL, phospholipid; TG, triacylglycerol.
a P , 0.05, day 8 versus day 1.
b P , 0.01, day 8 versus day 1.
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partments and is proportionally greater in infants with
lower birth weight (24, 25). The postnatal weight loss in the
MCT/LCT group (11.4%) is within the expected range of
7.3–14.5% (26). Weight gain can best be compared with
Z-scores for weight related to gender and age, which do
not differ between the two groups, suggesting that under
the conditions of our study the choice of the lipid emulsion
did not affect weight gain.
The observed plasma TG concentrations are within the
accepted reference range, and the results for PL and
nonesterified fatty acids are similar to previous reports for
premature neonates (27, 28). The increase in cholesterol
levels during the first days of life has been described in
previous studies after parenteral and enteral nutrition (29,
30). In agreement with previous studies, we found no ap-
preciable differences in plasma free carnitine and acylcar-
nitine values between the two groups (28). A significant
effect of MCT in the diet or of carnitine-free parenteral
nutrition might become apparent after longer periods,
but during short periods of parenteral nutrition carnitine
supplementation has no demonstrable benefits (31).
The control group showed lower g-tocopherol levels
on day 1 but a trend toward higher values on days 7 and
8 (NS), reflecting the higher content of g-tocopherol in
the LCT emulsion with its higher content of soybean
oil (32). The concentrations of a-tocopherol, the most
important lipid-soluble antioxidant, were similar with both
emulsions (Table 2) and well above the 12.4 Amol/l con-
sidered a threshold for vitamin E sufficiency in premature
neonates (33).
TGs from emulsions containing a MCT/LCT mixture
are hydrolyzed faster than those containing exclusively
LCT, apparently because of physicochemical effects of
MCT incorporated into the surface of emulsion particles
(34). The liberated medium-chain fatty acids are rapidly
oxidized largely independent of carnitine (35), but only
minor amounts are incorporated into plasma TG (Table 6).
In contrast to medium-chain fatty acids, long-chain fatty
acids are preferentially activated in the cytosol and esteri-
fied into TG and PL, and only a small proportion enters
the mitochondria via the carnitine cycle (35). It has been
suggested that during MCT/LCT ingestion, carnitine
palmitoyltransferase I is inhibited by the production of
malonyl-CoA, and consequently oxidation of long-chain
fatty acids is reduced and their incorporation into complex
lipids is enhanced (36). Indeed, we recently found reduced
LA oxidation in preterm infants fed an enteral formula with
40% of fat provided by MCT compared with a 100% LCT
formula (37). Even though the LCT emulsion provided ap-
proximately twice the amounts of palmitic acid (C16:0),
TABLE 6. Fatty acid composition of plasma TGs in preterm infants before (day 1) and after (day 8) LCT
(control) or MCT/LCT emulsion
Day 1 Day 8
Composition LCT (n 5 6) MCT/LCT (n 5 6) LCT (n 5 6) MCT/LCT (n 5 6)
Saturated fatty acids
C8:0 0.11 (0.03) 0.08 (0.03) 0.10 (0.12) 0.50 (0.60)a,b
C10:0 0.15 (0.06) 0.19 (0.09) 0.15 (0.17) 0.66 (0.51)a,b
C12:0 0.56 (0.13) 0.48 (0.10) 0.61 (0.27)a 0.89 (0.43)
C14:0 1.76 (0.22) 1.71 (0.24) 1.58 (0.62) 1.94 (0.34)
C16:0 34.69 (4.61) 33.21 (3.21) 25.21 (3.71)a 25.84 (2.31)c
C17:0 0.36 (0.10) 0.31 (0.07) 0.37 (0.07) 0.37 (0.05)
C18:0 6.16 (1.33) 4.66 (1.14) 3.34 (0.54)c 3.65 (0.37)
C20:0 0.06 (0.01) 0.04 (0.01)b 0.06 (0.07) 0.23 (0.45)
A SFA 44.52 (4.64) 40.02 (2.19) 32.09 (4.91) 33.45 (3.09)
Monounsaturated fatty acids
C18:1n-9 32.13 (5.90) 33.56 (4.84) 26.43 (3.02)a 27.24 (2.33)a
A MUFA 45.47 (7.46) 50.07 (4.15) 32.14 (4.72) 35.70 (2.70)
Polyunsaturated fatty acids
C20:3n-9 0.35 (0.12) 0.42 (0.11) 0.25 (0.19) 0.32 (0.10)c
n-6 PUFA
C18:2n-6 4.37 (1.85) 4.12 (1.67) 29.57 (9.22)c 23.37 (3.29)c
C18:3n-6 0.12 (0.06) 0.11 (0.06) 1.0 (0.57)a 0.85 (0.13)c
C20:2n-6 0.17 (0.02) 0.16 (0.02) 0.26 (0.06)a 0.33 (0.07)b,c
C20:3n-6 0.84 (0.22) 0.79 (0.27) 0.69 (0.28) 0.89 (0.09)
C20:4n-6 1.68 (1.10) 1.69 (0.73) 1.64 (0.87) 2.28 (0.49)
C22:4n-6 0.20 (0.13) 0.25 (0.07) 0.18 (0.08) 0.24 (0.05)
C22:5n-6 0.47 (0.24) 0.62 (0.12) 0.23 (0.15) 0.34 (0.09)c
n-3 PUFA
C18:3n-3 0.04 (0.03) 0.04 (0.03) 1.39 (1.11)a 0.97 (0.25)c
C20:3n-3 n.d. n.d. 0.01 (0.01) 0.04 (0.03)
C20:5n-3 0.02 (0.02) 0.03 (0.04) 0.11 (0.05)a 0.13 (0.04)a
C22:5n-3 0.01 (0.03) 0.03 (0.03) 0.03 (0.03) 0.05 (0.04)
C22:6n-3 0.78 (0.56) 1.13 (0.64) 0.27 (0.14) 0.47 (0.13)b
A PUFA 9.17 (3.53) 9.30 (2.78) 35.27 (8.77) 30.63 (3.62)
n.d., not detected. A PUFA = C18:2n-6 + C18:3n-6 + C20:2n-6 + C20:3n-6 + C20:4n-6 + C22:4n-6 + C22:5n-6 +
C18:3n-3 + C20:3n-3 + C20:5n-3 + C22:5n-3 + C22:6n-3. Values shown are means (SD) (%, w/w).
a P , 0.01 day 8 versus day 1 within one group.
b P , 0.05 MCT/LCT versus control.
c P , 0.05 day 8 versus day 1 within one group.
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stearic acid (C18:0), oleic acid (C18:1n-9), LA (C18:2n-6),
and ALA (C18:3n-3) as the MCT/LCT emulsion, plasma
levels of these fatty acids were rather similar in both groups,
except for a slightly higher LA (C18:2n-6) value in plasma
PL on day 8 in the LCT group (Table 5). This striking effect
may result in part from a decreased long-chain fatty acid
oxidation in the MCT/LCT group and thus incorporation
of a larger proportion of the long-chain fatty acids supplied
into plasma lipids. The trend toward slightly higher values
of palmitic (C16:0), stearic (C18:0), and oleic (C18:1n-9)
acids but slightly lower LA (C18:2n-6) and ALA (C18:3n-3)
in the MCT group, compared with the LCT group, might
reflect the greater oxidation of polyunsaturated fatty acids
than saturated fatty acids (38). Alternatively, long-chain sat-
urated fatty acids and oleic acid (C18:1n-9) might have been
synthesized in the MCT/LCT group from readily available
medium-chain fatty acids (39).
Over the course of the postnatal study period, EFAs
increased in plasma lipids, whereas LC-PUFAs decreased.
The observed values and their changes were similar to
those found in enterally fed preterm neonates and reflect
the change from placental fatty acid transfer, with a pref-
erential supply of LC-PUFAs (40), to a feeding regimen
supplying predominantly EFAs (9).
Polyunsaturated fatty acid turnover was assessed in this
study with 13C-labeled tracer fatty acids given orally with
small volumes of human milk. Plasma APE values of LA
(C18:2n-6) and ALA (C18:3n-3) in the MCT/LCT group
were significantly higher, presumably because plasma LA
(C18:2n-6) and ALA (C18:3n-3) pools were similar in the
groups and the tracer intake was higher in this group rela-
tive to the infused amounts of LA (C18:2-6) and ALA (C18:
3n-3). Thus, there was less dilution of the tracer before
incorporation into PLs or conversion to LC-PUFAs, which
would also explain the higher concentrations of 13C-labeled
LA (C18:2n-6), ALA (C18:3n-3), and their labeled deriva-
tives in the MCT/LCT group than in the control group.
Excessive availability of LA (C18:2n-6) or ALA (C18:3n-
3) may inhibit desaturase activity, which would influence
tracer distribution between precursor and product fatty
acids at 24 h after tracer intake, when samples were ob-
tained (41, 42). Based on lower DHA (C22:6n-3) incorpo-
ration in plasma PLs in preterm infants fed formulae with
MCT (43), it has been postulated that MCT might in-
terfere with the conversion of docosapentaenoic acid (DPA;
C22:5n-3) to DHA (C22:6n-3), which involves peroxisomal
chain shortening of a 24 carbon intermediate (44). How-
ever, the observed distribution of the tracer amounts be-
tween precursors and products was very similar between
groups for the n-6 series [LA, 82.5 6 4.2% vs. 84.8 6 7.8%
(MCT/LCT vs. LCT); dihomo g-linolenic acid (DGLA),
6.7 6 1.3% vs. 5.8 6 2.3%; AA, 10.8 6 3.0% vs. 9.5 6 5.6%]
and for the n-3 fatty acids [ALA, 7.3 6 3.2% vs. 12.1 6
8.9%; eicosapentaenoic acid (EPA), 22.0 6 5.1% vs.
25.0 6 8.7%; DPA, 17.7 6 3.2% vs. 19.6 6 4.9%; DHA,
52.9 6 9.5% vs. 43.3 6 12.7%]. Also, the 13C APE ratios
between product and precursor fatty acids were similar
between the two groups (AA/DGLA, 0.31 6 0.08 vs. 0.30 6
0.003; DGLA/LA, 0.69 6 0.11 vs. 0.70 6 0.10; DHA/DPA,
0.2460.09 vs. 0.2960.08; DHA/EPA, 0.1660.09 vs. 0.166
0.06). Thus, the relative conversion of EFAs to LC-PUFAs
is not influenced by the intake of MCT or the intake of LA
(C18:2n-6) and ALA (C18:3n-3) under the conditions of
this study. Also, the MCT supply with the lipid emulsion
seems not to influence the relative incorporation of the
different n-6 and n-3 fatty acids into plasma PLs. For the n-6
series, most of the tracer is found in LA (C18:2n-6), whereas
in the n-3 series, the distribution is skewed toward DHA
(C22:6n-3), reflecting the fact that LA (C18:2n-6) is the
most abundant n-6 fatty acid, whereas DHA shows the
highest percentage contribution of the n-3 fatty acids. Of
importance, the tracer distribution depends on the relative
incorporation of individual fatty acids in PLs but does
Fig. 2. Tracer concentrations in plasma PL fatty acids of preterm
infants after 7 days of intravenous lipid infusion 24 h after tracer
intake. Open bars, control group, soybean oil; closed bars, MCT/
LCT group. Values shown are means 6 SD. * P , 0.05 between
groups.
Fig. 1. 13C atom percent excess (APE) in plasma phospholipid
(PL) fatty acids of preterm infants after 7 days of intravenous lipid
infusion 24 h after tracer intake. Open bars, control group,
soybean oil; closed bars, medium-chain triacylglycerol/long-chain
triacylglycerol (MCT/LCT) group. Values shown are means 6 SD.
* P , 0.05 between groups. AA, arachidonic acid; ALA, a-linolenic
acid; DGLA, dihomo g-linolenic acid; DHA, docosahexaenoic acid;
DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; LA,
linoleic acid.
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not indicate a higher relative LC-PUFA synthesis in the
n-3 series.
Given no detectable differential effect of the emulsions
on the relative conversion of precursors to LC-PUFAs,
the trend toward higher LC-PUFA values in the MCT/
LCT group appears to result from reduced LC-PUFA oxi-
dation. In animal studies, dietary LC-PUFAs are oxidized
to a limited extent but are preferentially incorporated into
structural lipids and oxidized to a lower extent than other
fatty acids (saturated, monounsaturated, LA, ALA) (45,
46). We presume that the parenteral MCT supply has
effectively reduced LC-PUFA oxidation and, thereby, in-
duced the trend toward increased LC-PUFA contents in
plasma lipids.
In contrast to LC-PUFAs, the EFA intermediateg-linolenic
acid (C18:3n-6) showed significantly higher contents in PLs
of the control group, which was also found after longer
infusion periods in adults (42) but not after 5 days of lipid
infusion in neonates (28). We could not determine tracer
contents in g-linolenic acid (C18:3n-6) in the small samples
available from these preterm infants and thus can only
speculate that a rapid exchange between the relatively large
LA (C18:2n-6) pool and the relatively small g-linolenic acid
(C18:3n-6) pool might be the underlying metabolic cause.
We conclude that the use of the MCT/LCT emulsion in
parenteral nutrition of preterm infants for a period of
8 days is well tolerated and provides equivalent carnitine,
vitamin E, and EFA status compared with the LCT emul-
sion. The concentration of the functionally important n-3
fatty acid DHA (C22:6n-3) was higher in plasma TG of the
MCT/LCT group, and there is also a trend toward higher
levels of other LC-PUFAs in TG and PL. Because the avail-
ability of LC-PUFAs, and particularly of DHA (C22:6n-3),
was shown to be of great functional importance in early life
for the development of visual acuity (7) and cognitive de-
velopment (6), the use of the MCT/LCT emulsion might
provide important clinical benefits over the use of a stan-
dard soybean oil emulsion in these patients.
Statistical analyses were performed by D. Osterkorn and K.
Osterkorn (Medizinisches Wirtschaftsinstitut GmbH, Munich,
Germany). This study was financially supported in part by the
Deutsche Forschungsgemeinschaft (Bonn, Germany; Ko 912/
5-1 and Ko 912/5-2), B. Braun (Melsungen, Germany), and the
Child Health Foundation (Munich, Germany).
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